The European Commission on Wednesday announced that Sanofi (SNY) has agreed to stop disparaging a rival flu vaccine developed by CSL Limited (CSLLY) after the French drugmaker faced an EU antitrust ...
Alongside the U.S. government’s overhaul of the federal vaccine infrastructure, influenza vaccination rates in the country have plummeted below the expectations of a key player in the space. That ...
SYDNEY--Australia-based pharmaceutical company CSL is delaying a plan to spin off its flu-vaccine business and cut its annual guidance amid declining vaccination rates in the U.S. CSL previously ...
The comment-seeking period and probe tie back to Sanofi’s marketing for its flu shot for adults ages 60 and over, which is ...
SYDNEY--Shares in Australia-based pharmaceutical company CSL tumbled 15% on Tuesday after the company delayed the spinoff of its flu vaccine unit and cut annual guidance. In late morning trade Tuesday ...
SYDNEY (Reuters) -Australian biotech CSL has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu immunisation rates, which knocked its ...
SUMMIT, N.J., Oct. 21, 2025 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), announced recent data showing that cell-based influenza vaccines offer greater protection in preventing ...
The CSL Ltd (ASX: CSL) share price is in focus today as the company opens its 2025 Capital Markets Day in Chicago, highlighting continued global leadership in influenza vaccines and robust long-term ...
Oct 30 (Reuters) - Australia's CSL (CSL.AX), opens new tab said on Thursday its vaccine arm, CSL Seqirus and Vaccine Industrial Company, had inked a deal with Saudi Arabia's Health Ministry to ...
April 23 (Reuters) - Australian biotech giant CSL extended losses on Thursday, lingering near decade lows, after the U.S. military scrapped its flu vaccine mandate, dealing another blow to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results